FDA Clearance Tracker · P150031-S028
Vercise Deep Brain Stimulation (DBS) System
Last checked: Nov 20, 2026Latest source record: Dec 29, 2020 (this decision)Source: openFDAMethods & limitations
Decided
Dec 29, 2020
Approved
Time to decision
365 days
Received Dec 30, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P150031-S028
- Device name
- Vercise Deep Brain Stimulation (DBS) System
- Applicant
- Boston Scientific Corp
- Applicant location
- Valencia, CA
- Received
- Dec 30, 2019
- Decided
- Dec 29, 2020
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P150031
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the Vercise PC and Vercise Gevia DBS Systems for expanding the indications to include bilateral stimulation of the internal globus pallidus (GPi) as an adjunctive therapy to reduce some of the symptoms of advanced levodopa-responsive Parkinsons disease that is not adequately controlled by medications.
Source documents
Other decisions for Boston Scientific Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P130030 · Decided Mar 10, 2026 · 4,453 days after receipt
Device type: STENT, CORONARY (MAF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.